Genomics and Pharmacogenomics in Anticancer Drug Development and Clinical Response / Edition 1

Hardcover (Print)
Buy New
Buy New from BN.com
$246.05
Used and New from Other Sellers
Used and New from Other Sellers
from $64.57
Usually ships in 1-2 business days
(Save 75%)
Other sellers (Hardcover)
  • All (7) from $64.57   
  • New (5) from $93.23   
  • Used (2) from $64.57   

Overview

The availability of new molecular approaches to the selection of drug therapy is an emerging need, as the traditional approach based on the evaluation of patient and tumor characteristics is clearly far from optimal. Many, and in most cases the majority of treated patients do not have significant benefits from the treatment while they often experience moderate to severe toxicities. In “Pharmacogenomics, Anticancer Drug Discovery, and Response”, edited by Federico Innocenti, readers will find a series of chapters addressing the role of genomic information in cancer therapy and in drug development representing a unique source, as it describes experimental approaches, statistical strategies, and clinical examples of the application of genomic medicine in oncology. This book provides the most comprehensive body of knowledge on the role of genetic and genomic variation in the individualization of drug therapies in cancer patients.

Read More Show Less

Editorial Reviews

From the Publisher
From the reviews:

"The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics, clearly show how DNA information from both the host and the tumor should be taken into account for rational selection of drug therapies in cancer patients. … the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, June, 2009)

"The chapters of this book, written by outstanding scientists in the field of cancer pharmacogenomics … . the book provides a comprehensive and in-depth view of the field of cancer pharmacogenomics. The book is informative for clinicians, for people involved in development of cancer therapeutics on industrial level, and any scientists who are interested in cancer biology." (C. Altaner, Neoplasma, April, 2009)

Read More Show Less

Product Details

  • ISBN-13: 9781588296467
  • Publisher: Springer-Verlag New York, LLC
  • Publication date: 10/17/2008
  • Series: Cancer Drug Discovery and Development Series
  • Edition description: 2009
  • Edition number: 1
  • Pages: 378
  • Product dimensions: 7.70 (w) x 10.30 (h) x 1.00 (d)

Table of Contents

pharmacoGENOMICS, ANTICANCER DRUG DISCOVERY, AND RESPONSE

Book editor: Federico Innocenti, M.D., Ph.D.

Genomic experimental approaches in oncology

  1. Toward the realisation of the promise of microarrays in oncology
  2. Neil Winegarden

  3. Cell based models to identify genetic variants contributing to anticancer drug response
  4. M. Eileen Dolan

  5. Proteomic analysis in cancer patients
  6. Kazuyuki Nakamura

  7. MicroRNAs and discovery of new targets
  8. Gozoh Tsujimoto

  9. Pharmacogenomics of the National Cancer Institute’s 60 tumor cell panel
  10. David G. Covell

  11. Use of single nucleotide polymorphism array for tumor aberrations in gene copy numbers

Kwong-Kwok Wong

Pharmacogenomics of toxicity and response of chemotherapy

  1. Concordance between tumor and germline DNA
  2. Sharon Marsh

  3. Epidermal growth factor receptor mutations and sensitivity to selective kinase inhibitors in human lung cancer

Jeffrey Settleman

3. BCR-ABL mutations and imatinib resistance in chronic myeloid leukemia patients

Mark Litzow

  1. Role of thymidylate synthase gene variations in colorectal cancer patients
  2. Heinz-Josef Lenz

  3. Thiopurines in the treatment of childhood acute lymphoblastic leukemia and genetic variants in the thiopurine S-methyltransferase gene
  4. Martin Stanulla

  5. The impact of polymorphisms on the clinical outcomes of monoclonal antibody therapy against hematologic malignancies
  6. Dong Hwan Kim

  7. DNA repair and mitotic check point genes as potential predictors of chemotherapy response in non-small-cell lung cancer
  8. Rafael Rosell

  9. Dihydropyrimidine dehydrogenase (DPYD) gene polymorphism: portrait of a serial killer.
  10. Gerard Milano

  11. Impact of UDP-glucuronosyltransferase 1A haplotypes on irinotecan treatment
  12. Kimie Sai

  13. Microarray profiling in breast cancer patients

Lan Guo

11. Role of the folate pathway and the thymidylate synthase genes in pediatric acute lymphoblastic leukemia treatment response

Richard Aplenc

Pharmacogenomics in clinical drug development in oncology

  1. Pharmacogenomics in drug development: an pharmaceutical industry perspective
  2. Tal Zaks

  3. Identification of a pharmacogenomic biomarker classifiers in cancer drug development
  4. Richard Simon

  5. Toxicogenomics application to oncology drug development
  6. Teresa Lettieri

  7. Strategies to identify pharmacogenomic biomarkers: candidate gene, pathway-based, and genome-wide approaches

Xifeng Wu

Read More Show Less

Customer Reviews

Be the first to write a review
( 0 )
Rating Distribution

5 Star

(0)

4 Star

(0)

3 Star

(0)

2 Star

(0)

1 Star

(0)

Your Rating:

Your Name: Create a Pen Name or

Barnes & Noble.com Review Rules

Our reader reviews allow you to share your comments on titles you liked, or didn't, with others. By submitting an online review, you are representing to Barnes & Noble.com that all information contained in your review is original and accurate in all respects, and that the submission of such content by you and the posting of such content by Barnes & Noble.com does not and will not violate the rights of any third party. Please follow the rules below to help ensure that your review can be posted.

Reviews by Our Customers Under the Age of 13

We highly value and respect everyone's opinion concerning the titles we offer. However, we cannot allow persons under the age of 13 to have accounts at BN.com or to post customer reviews. Please see our Terms of Use for more details.

What to exclude from your review:

Please do not write about reviews, commentary, or information posted on the product page. If you see any errors in the information on the product page, please send us an email.

Reviews should not contain any of the following:

  • - HTML tags, profanity, obscenities, vulgarities, or comments that defame anyone
  • - Time-sensitive information such as tour dates, signings, lectures, etc.
  • - Single-word reviews. Other people will read your review to discover why you liked or didn't like the title. Be descriptive.
  • - Comments focusing on the author or that may ruin the ending for others
  • - Phone numbers, addresses, URLs
  • - Pricing and availability information or alternative ordering information
  • - Advertisements or commercial solicitation

Reminder:

  • - By submitting a review, you grant to Barnes & Noble.com and its sublicensees the royalty-free, perpetual, irrevocable right and license to use the review in accordance with the Barnes & Noble.com Terms of Use.
  • - Barnes & Noble.com reserves the right not to post any review -- particularly those that do not follow the terms and conditions of these Rules. Barnes & Noble.com also reserves the right to remove any review at any time without notice.
  • - See Terms of Use for other conditions and disclaimers.
Search for Products You'd Like to Recommend

Recommend other products that relate to your review. Just search for them below and share!

Create a Pen Name

Your Pen Name is your unique identity on BN.com. It will appear on the reviews you write and other website activities. Your Pen Name cannot be edited, changed or deleted once submitted.

 
Your Pen Name can be any combination of alphanumeric characters (plus - and _), and must be at least two characters long.

Continue Anonymously

    If you find inappropriate content, please report it to Barnes & Noble
    Why is this product inappropriate?
    Comments (optional)